WebMar 1, 2024 · Key Objective. Chemoradiotherapy with 3-weekly cisplatin at a dose of 100 mg/m 2 is the standard treatment for patients with postoperative locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) with high risk for … Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG … WebApr 12, 2024 · Plain language summary Head and neck cancer is one of the main causes of cancer-related death worldwide. Most patients are diagnosed in the advanced stage. ... dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. Head Neck 44(1), 189–200 (2024).
Low- Versus Standard-Dose Cisplatin for Locally Advanced …
WebNov 23, 2024 · Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Merck Sharp & Dohme. Merck Sharp & Dohme. WebNov 21, 2024 · Save this study Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. popjoy hideout
Cisplatin - NCI - National Cancer Institute
WebAbstract. In 22 patients with advanced squamous cell carcinoma of the head and neck we evaluated the efficacy and toxicity of 200 mg/m2 cisplatin administered in 3% NaCl with … WebBackground: For definitive chemoradiotherapy (chemoRT) of head and neck squamous cell carcinoma (HNSCC), cisplatin is the preferred concurrent agent, with superiority over cetuximab for HPV-associated oropharyngeal squamous carcinoma recently shown in 2 randomized trials (RTOG 1016 and De-ESCALaTE). Patients who are not candidates for … WebJun 4, 2024 · Weekly cisplatin plus radiotherapy (RT) should be considered standard care in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), … shares tyl